fashion -WSS

fashion

author：hotspot 2025-08-24 10:13:45 - browse：9856

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Why the quest to eradicate polio has stumbled

explore

WSS

FDA panel to weigh safety of artificial wombs for preterm births

House panel takes first step toward fixing drug shortages

House panel takes first step toward fixing drug shortages

Midwives could help bridge maternal health disparities in the U.S.

Patients, doctors press FTC to beef up hospital merger scrutiny

FDA weighs limits of animal data in assessing artificial wombs

knowledge

fashion

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Patients, doctors press FTC to beef up hospital merger scrutiny

BioMarin wins approval for gene therapy to treat hemophilia A

FDA weighs limits of animal data in assessing artificial wombs

United colonoscopy coverage change 'may cost lives,' doctors say

How the messy conversation about Dolly changed bioethics

The cancer drug shortage isn’t new — and neither are the solutions

FDA panel to weigh safety of artificial wombs for preterm births

Medicare proposal to cover medical devices draws a mixed reaction

'A game

Wikipedia

House panel takes first step toward fixing drug shortages

Senate bill would ban some hospital facility fees

David Liu startup to focus on CRISPR delivery

PBMs drew scrutiny in House hearing — and so did pharma

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Midwives could help bridge maternal health disparities in the U.S.

knowledge

explore

Wikipedia

knowledge